• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Safety of First Trimester Ondansetron Exposure During Pregnancy

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Ondansteron, a 5-HT3 receptor agonist, is used to treat nausea and vomiting in pregnancy
  • Safety data on the association between ondansetron and birth defects are limited
  • Huybrechts et al. (JAMA., 2018) sought to evaluate whether ondansetron exposure during pregnancy is associated with risk of congenital malformations, with a focus on cardiac and oral clefting defects

METHODS:

  • Retrospective cohort study
    • Data derived from the nationwide Medicaid Analytic eXtract (MAX)
    • Pregnant women registered 3 months before the last menstrual period through 1 month or longer after delivery
  • Data analyzed comparing
    • Ondansetron (exposure) during the first trimester vs control group
  • Primary outcomes (diagnosed during the first 90 days after delivery)
    • Cardiac malformations
    • Oral clefts
  • Secondary outcomes included
    • Congenital malformations overall
    • Subgroups of cardiac malformations and oral clefts

RESULTS:

  • 1,816,414 pregnancies were included
    • Mean maternal age: 24.3 years
    • 88,467 (4.9%) were exposed to ondansetron during the first trimester
  • Cardiac Malformations (absolute risk)
    • Unexposed: 84.4 per 10,000 births ( 95% CI, 83.0 to 85.7)
    • Exposed: 94.4 per 10,000 births (95% CI, 88.0 to 100.8)
  • Oral clefts (absolute risk)
    • Unexposed: 11.1 per 10,000 births (95% CI, 10.6 to 11.6)
    • Exposed: 14.0 per 10,000 births (95% CI, 11.6 to 16.5)
  • Any congenital malformation (absolute risk)
    • Unexposed: 313.5 per 10,000 births (95% CI, 310.9 to 316.1)
    • Exposed: 370.4 per 10,000 births (95% CI, 358.0 to 382.9)
  • Cardiac malformations (relative risk)
    • Adjusted relative risk (RR): 0.99 (95% CI, 0.93 to 1.06)
  • Oral clefts (relative risk)
    • Adjusted RR: 1.24 (95% CI, 1.03 to 1.48)
  • Congenital malformations (relative risk)
    • Adjusted RR: 1.01 (95% CI, 0.98 to 1.05)

CONCLUSION:

  • First-trimester exposure to ondansetron was not associated with cardiac malformations or overall congenital malformations
  • There may be a “small increased risk of oral clefts”

Learn More – Primary Sources:

Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Practical obstetrics info for your women's healthcare practice
Nausea and Vomiting in Pregnancy – Management Options for Hyperemesis Gravidarum
Ondansetron for Nausea During Pregnancy – Is There a Risk for Birth Defects?
Practical obstetrics info for your women's healthcare practice
Cleft Lip and Palate – Considerations and Discussion Points

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site